Targeting βIII-tubulin in glioblastoma multiforme: From cell biology and histopathology to cancer therapeutics

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 719-728

  Katsetos, Christos D ^a   Dráber, Pavel ^b   Kavallaris, Maria ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Epothilones; Glioblastoma multiforme; TBA; Tubulin; Tubulin binding agent(s)

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BETA TUBULIN; BETA3 TUBULIN; COUMARIN; CYCLIN DEPENDENT KINASE 1; CYCLOSTREPTIN; ELEUTHEROBIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMIASTERLIN DERIVATIVE; IXABEPILONE; LAULIMALIDE; MICROTUBULE ASSOCIATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; POLYMER; SAGOPILONE; SECOTAXOID DERIVATIVE; TACCALONOLIDE DERIVATIVE; TASIDOTIN; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADVANCED CANCER; ANAPHASE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING SITE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER STEM CELL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SHAPE; CELL TYPE; CYTOLOGY; DNA POLYMORPHISM; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIZATION; EUKARYOTE; GENE OVEREXPRESSION; GLIOBLASTOMA; GLYCOSYLATION; HISTOPATHOLOGY; HUMAN; HYPOXIA; MAMMAL CELL; MEDULLOBLASTOMA; MELANOMA; MICROTUBULE; MICROTUBULE ORGANIZING CENTER; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; OXIDATIVE STRESS; PHOSPHORYLATION; POINT MUTATION; POLYMERIZATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TUMOR CELL; TUMOR GROWTH;

EID: 80053555640     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378760     Document Type: Review

References (108)

1. Ohgaki, H.; Kleihues, P. Population-based studies on incidence,survival rates, and genetic alterations in astrocytic and oligodendroglialgliomas. J Neuropathol Exp Neurol. 2005, 64, 479-489.
2. Jordan, M.A.; Wilson, L. Microtubules and actin filaments: dynamictargets for cancer chemotherapy. Curr Opin Cell Biol. 1998,10, 123-130.
3. Pasquier, E.; Kavallaris, M. Microtubules: a dynamic target incancer therapy. IUBMB Life. 2008, 60, 165-170.
4. Dumontet, C; Jordan, M.A. Microtubule-binding agents: adynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010,9, 790-803.
5. Whipple, R.A.; Cheung, A.M.; Martin, S.S. Detyrosinated microtubuleprotrusions in suspended mammary epithelial cells promotereattachment. Exp Cell Res. 2007, 313, 1326-1336.
6. Schoumacher, M.; Goldman, R.D.; Louvard, D.; Vignjevic, D.M.Actin, microtubules, and vimentin intermediate filaments cooperatefor elongation of invadopodia. J Cell Biol. 2010, 189, 541-556.
7. Liaw, T.Y.; Chang, M.H.; Kavallaris, M. The cytoskeleton as atherapeutic target in childhood acute leukemia: obstacles and opportunities.Curr Drug Targets. 2007, 8, 739-749.
8. Ferlini, C.; Raspaglio, G.; Cicchillitti, L.; Mozzetti, S.; Prislei, S.; Bartollino, S.; Scambia, G. Looking at drug resistance mechanismsfor microtubule interacting drugs: does TUBB3 work? Curr CancerDrug Targets. 2007, 7, 704-712.
9. Katsetos, C.D.; Dráberová, E.; Legido, A.; Dumontet, C.; Dráber, P. Tubulin targets in the pathobiology and therapy of glioblastomamultiforme. I. Class III β-tubulin. J Cell Physiol. 2009, 221,505-513.
10. Kavallaris, M. Microtubules and resistance to tubulin-bindingagents. Nat Rev Cancer. 2010, 10, 194-204.
11. Régina, A.; Demeule, M.; Ché, C.; Lavallée, I.; Poirier, J.;Gabathuler, R.; et al. Antitumour activity of ANG1005, a conjugatebetween paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008, 155, 185-197
12. Mielke, S.; Sparreboom, A.; Mross, K. Peripheral neuropathy: apersisting challenge in paclitaxel-based regimes. Eur J Cancer.2006, 42, 24-30.
13. Baas, P.W.; Karabay, A.; Qiang, L. Microtubules cut and run.Trends Cell Biol. 2005, 15, 518-524.
14. Richter-Landsberg, C. The cytoskeleton in oligodendrocytes. Microtubule dynamics in health and disease. J Mol Neurosci. 2008,35, 55-63.
15. Shi, J.; Orth, J.D.; Mitchison, T. Cell type variation in responses toantimitotic drugs that target microtubules and kinesin-5. CancerRes. 2008, 68, 3269-3276.
16. Hornick, J.E.; Karanjeet, K.; Collins, E.S.; Hinchcliffe, E.H. Kinesins to the core: The role of microtubule-based motor proteinsin building the mitotic spindle midzone. Semin Cell Dev Biol. 2010,21, 290-299
17. Dráberová, E.; Vinopal, S.; Morfini, G.; Liu, P.S.; Sládková, V.; Sulimenko, T.; Burns, M.R.; Solowska, J.; Kulandeival, K.; deChadarevian, J.-P.; Legido, A.; Mörk, S.J.; Janácek, J.; Baas, P.W.; Dráber, P.; Katsetos, C.D. Microtubule severing ATPase spastin inglioblastoma multiforme: Increased expression in human glioblastomacell lines and roles in cell motility and proliferation. J.Neuropathol. Exp. Neurol., 2011, 70, 811-826.
18. Katsetos, C.D.; Del Valle, L; Geddes, J.F.; Assimakopoulou, M.; Legido, A; Boyd, J.C.; Balin, B.; Parikh, N.A.; Maraziotis, T.; de Chadarevian, J.P.; Varakis, J.N.; Matsas, R.; Spano, A.; Frankfurter, A.; Herman, M.M.; Khalili, K. Aberrant localization ofthe neuronal class III β-tubulin in astrocytomas. Arch Pathol LabMed. 2001, 125, 613-624.
19. Katsetos, C.D.; Del Valle, L.; Geddes, J.F.; Aldape, K.; Boyd, J.C.; Legido, A.; Khalili, K.; Perentes, E.; Mörk, S.J. Localization of theneuronal class III β-tubulin in oligodendrogliomas: comparisonwith Ki-67 proliferative index and 1p/19q status. J NeuropatholExp Neurol. 2002, 61, 307-320.
20. Katsetos, C.D.; Herman, M.M.; Mörk, S.J. Class III β-tubulin inhuman development and cancer. Cell Motil Cytoskeleton. 2003, 55,77-96.
21. Katsetos, C.D.; Legido, A.; Perentes, E.; Mörk, S.J. Class III β-tubulin isotype: a key cytoskeletal protein at the crossroads ofdevelopmental neurobiology and tumor neuropathology. J ChildNeurol. 2003, 18, 851-866.
22. Katsetos, C.D.; Reddy, G.; Dráberová, E.; mejkalová, B.; DelValle, L.; Ashraf, Q.; Tadevosyan, A.; Yelin, K.; Maraziotis, T.; Mishra, O.P.; Mörk, S.; Legido, A.; Nissanov, J.; Baas, P.W.; de Chadarévian, J.-P.; Dráber, P. Altered cellular distribution andsubcellular sorting of -tubulin in astrocytic gliomas andhuman glioblastoma cell lines. J Neuropathol Exp Neurol. 2006,65, 465-477.
23. Katsetos, C.D.; Dráberová, E.; mejkalová, B.; Reddy, G.; Bertrand, L.; de Chadarévian, J.-P.; Legido, A.; Nissanov, J.; Baas, P.W.; Dráber, P. Class III β-tubulin and -tubulin are co-expressedand form complexes in human glioblastoma cells. Neurochem Res.2007, 32, 1387-1398.
24. Katsetos, C.D.; Dráberová, E.; Legido, A.; Dráber, P. Tubulintargets in the pathobiology and therapy of glioblastoma multiforme.II. -Tubulin. J Cell Physiol. 2009, 221, 514-520.
25. Ludueña, R.F. The multiple forms of tubulin: different geneproducts and covalent modifications. Int Rev Cytol. 1998, 178,207-275.
26. Mitchison, T.; Kirschner, M. Dynamic instability of microtubulegrowth. Nature. 1984, 312, 237-242.
27. Doxsey, S. Re-evaluating centrosome function. Nat Rev Mol CellBiol. 2001, 2, 688-698.
28. Ludueña, R.F.; Banerjee, A. The isotypes of tubulin: distributionand functional significance. In: Cancer Drug Discovery and Development:The Role of Microtubules in Cell Biology, Neurobiology,and Oncology, Fojo, T., Ed., Humana Press, Totowa, NJ; 2008, pp.123-175
29. Verdier-Pinard, P.; Pasquier, E.; Xiao, H.; Burd, B.; Villard, C.; Lafitte, D.; Miller, L.M.; Angeletti, R.H.; Horwitz, S.B.; Braguer, D. Tubulin proteomics: towards breaking the code. Anal Biochem.2009, 384,197-206.
30. Downing, K.H.; Nogales, E. Tubulin and microtubule structure. Curr Opin Cell Biol. 1998, 10, 16-22.
31. Jordan, M.A.; Kamath, K. How do microtubule-targeted drugswork? An overview. Curr Cancer Drug Targets. 2007, 7, 730-742.
32. Linhartová, I.; Dráber, P.; Dráberová, E.; Viklick-, V. Immunologicaldiscrimination of β-tubulin isoforms in developing mousebrain. Post-translational modification of non-class-III β-tubulins.Biochem J. 1992, 288, 919-924.
33. Alexander, J.E.; Hunt, D.F.; Shabanowitz, J.; Michel, H.; Berlin, S.C.; MacDonald, T.L.; Sundberg, R.J.; Rebhun, L.I.; Frankfurter, A. Characterization of posttranslational modifications in neuronspecific class III β-tubulin by mass spectrometry. Proc Natl AcadSci USA. 1991, 88, 4685-4689.
34. Mary, J.; Redeker, V.; Le Caer, J.P.; Promé, J.C.; Rossier, J. Class Iand IVa β-tubulin isotypes expressed in adult mouse brain are glutamylated. FEBS Lett. 1994, 353, 89-94.
35. Cicchillitti, L.; Penci, R.; Di Michele, M.; Filippetti, F.; Rotilio, D.; Donati, M.B.; Scambia, G.; Ferlini, C. Proteomic characterizationof cytoskeletal and mitochondrial class III β -tubulin. Mol CancerTher. 2008, 7, 2070-2079.
36. Westermann, S.; Weber, K. Post-translational modifications regulatemicrotubule function. Nat Rev Mol Cell Biol. 2003, 4, 938-947.
37. Verhey, K.J.; Gaertig, J. The tubulin code. Cell Cycle. 2007, 6,2152-2160.
38. Ludueña, R.F.; Banerjee, A. The post-translational modifications oftubulin. In: Cancer Drug Discovery and Development: The Role ofMicrotubules in Cell Biology, Neurobiology, and Oncology (FojoT, ed.), 2008, pp. 105-121, Humana Press, Totowa, NJ.
39. Joe, P.A.; Banerjee, A.; Ludueña, R.F. The roles of cys124 andser239 in the functional properties of human betaIII tubulin. CellMotil Cytoskeleton. 2008, 65, 476-486.
40. Khan, I.A.; Ludueña, R.F. Phosphorylation of βIII-tubulin. Biochemistry.1996, 35, 3704-3711.
41. Joe, P.A.; Banerjee, A.; Ludueña, R.F. Roles of β-tubulin residuesAla428 and Thr429 in microtubule formation in vivo. J Biol Chem.2009, 284, 4283-4291.
42. Dráberová, E.; Luká-, Z.; Ivanyi, D.; Viklick-, V.; Dráber, P. Expressionof class III β-tubulin in normal and neoplastic human tissues. Histochem Cell Biol. 1998, 109, 231-239.
43. Katsetos, C.D.; Herman, M.M.; Frankfurter, A.; Uffer, S.; Perentes, E.; Rubinstein, L.J. Neuron-associated class III β-tubulin isotype,microtubule-associated protein 2, and synaptophysin in human retinoblastomasin situ. Further immunohistochemical observations onthe Flexner-Wintersteiner rosettes. Lab Invest. 1991, 64, 45-54.
44. Katsetos, C.D.; Frankfurter, A.; Christakos, S.; Mancall, E.L.; Vlachos, I.; Urich, H. Differential localization of class III β-tubulinisotype and calbindin-D28k defines distinct neuronal types in thedeveloping human cerebellar cortex. J Neuropathol Exp Neurol.1993, 52, 655-666.
45. Katsetos, C.D.; Karkavelas, G.; Herman, M.M.; Vinores, S.A.; Provencio, J.; Spano, A.J.; Frankfurter, A. Class III β-tubulin isotype(βIII) in the adrenal medulla: I. Localization in the developinghuman adrenal medulla. Anat Rec. 1998, 250, 335-343.
46. Kukharskyy, V.; Sulimenko, V.; Macrek, L.; Sulimenko, T.; Dráberová, E.; Dráber, P. Complexes of -tubulin with nonreceptorprotein tyrosine kinases Src and Fyn in differentiating P19embryonal carcinoma cells. Exp Cell Res. 2004, 298, 218-228.
47. Dráberová, E.; del Valle, L.; Gordon, J.; Marková, V.; mejkalová, B.; Bertrand, L.; de Chadarévian, J.-P.; Agamanolis, D.P.; Legido, A.; Khalili, K.; Dráber, P.; Katsetos, C.D. Class III β-tubulin isconstitutively coexpressed with glial fibrillary acidic protein andnestin in midgestational human fetal astrocytes: implications forphenotypic identity. J Neuropathol Exp Neurol. 2008, 67, 341-354.
48. Sève, P.; Dumontet, C. Is class III β-tubulin a predictive factor inpatients receiving tubulin-binding agents? Lancet Oncol. 2008, 9,168-175.
49. Dumontet, C.; Jordan, M.A.; Lee, F.F. Ixabepilone: targeting _IIItubulinexpression in taxane-resistant malignancies. Mol CancerTher. 2009, 8, 17-25.
50. McCarroll, J.A.; Gan, P.P.; Liu, M.; Kavallaris, M. _III-Tubulinis a multifunctional protein involved in drug sensitivity andtumorigenesis in non-small cell lung cancer. Cancer Res. 2010, 70,4995-5003.
51. Katsetos, C.D.; Del Valle, L.; Legido, A.; de Chadarevian, J.-P.; Perentes, E.; Mörk, S.J. On the neuronal/neuroblastic nature of medulloblastomas:a tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol (Berl). 2003, 105, 1-13.
52. Caracciolo, V.; D'Agostino, L.; Dráberová, E.; Sládková, V.; Crozier-Fitzgerald, C.; Agamanolis, D.P.; de Chadarévian, J.-P.; Legido, A.; Giordano, A.; Dráber, P.; Katsetos, C.D. Differential expressionand cellular distribution of γ-tubulin and _III-tubulin in medulloblastomasand human medulloblastoma cell lines. J Cell Physiol.2010, 223, 519-529.
53. Mao, Y.; Zhou, L.; Zhu, W.; Wang, X.; Yang, G.; Xie, L.; Mao, X.; Jin, K. Proliferative status of tumor stem cells may be correlatedwith malignancy grade of human astrocytomas. Front Biosci. 2007,12, 2252-2259.
54. Ikota, H.; Kinjo, S.; Yokoo, H.; Nakazato, Y. Systematic immunohistochemicalprofiling of 378 brain tumors with 37 antibodies usingtissue microarray technology. Acta Neuropathol (Berl). 2006,111, 475-482.
55. Martinez-Diaz, H.; Kleinschmidt-DeMasters, B.K.; Powell, S.Z.; Yachnis, A.T. Giant cell glioblastoma and pleomorphic xanthoastrocytomashow different immunohistochemical profiles for neuronalantigens and p53 but share reactivity for class III β-tubulin.Arch Pathol Lab Med. 2003, 127, 1187-1191.
56. Lopes, M.B.; Frankfurter, A.; Zientek, G.M.; Herman, M.M. Thepresence of neuron-associated microtubule proteins in the humanU-251 MG cell line. A comparative immunoblot and immunohistochemicalstudy. Mol Chem Neuropathol. 1992, 17, 273-287.
57. Walton, N.M.; Snyder, G.E.; Park, D.; Kobeissy, F.; Scheffler, B.; Steindler, D.A. Gliotypic neural stem cells transiently adopt tumorigenicproperties during normal differentiation. Stem Cells.2009, 27, 280-289.
58. Rieske, P.; Golanska, E.; Zakrzewska, M.; Piaskowski, S.; Hulas-Bigoszewska, K.; Wola-czyk, M.; Szybka, M.; Witusik-Perkowska, M.; Jaskolski, D.J.; Zakrzewski, K.; Biernat, W.; Krynska, B.; Liberski, P.P. Arrested neural and advanced mesenchymaldifferentiation of glioblastoma cells-comparative study with neuralprogenitors. BMC Cancer. 2009, 9, 54.
59. Rieske, P.; Azizi, S.A.; Augelli, B.; Gaughan, J.; Krynska, B. Apopulation of human brain parenchymal cells express markers ofglial, neuronal and early neural cells and differentiate into cells ofneuronal and glial lineages. Eur J Neurosci. 2007, 25, 31-33.
60. Louis, D.N. Molecular pathology of malignant gliomas. Annu RevPathol. 2006, 1, 97-117.
61. Fischer, I.; Gagner, J.P.; Law, M.; Newcomb, E.W.; Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology.Brain Pathol. 2005, 15, 297-310.
62. Rong, Y.; Durden, D.L.; Van Meir, E.G.; Brat, D.J. Pseudopalisading'necrosis in glioblastoma: a familiar morphologic feature thatlinks vascular pathology, hypoxia, and angiogenesis. J NeuropatholExp Neurol. 2006, 65, 529-539.
63. Lam-Himlin, D.; Espey, M.G.; Perry, G.; Smith, M.A.; Castellani, R.J. Malignant glioma progression and nitric oxide. Neurochem Int.2006, 49, 764-768.
64. Fiore, G.; Di Cristo, C.; Monti, G.; Amoresano, A.; Columbano, L.; Pucci, P.; Cioffi, F.A.; Di Cosmo, A.; Palumbo, A.; d'Ischia, M.Tubulin nitration in human gliomas. Neurosci Lett. 2006, 394,57-62.
65. Merighi, S.; Benini, A.; Mirandola, P.; Gessi, S.; Varani, K.; Leung, E.; Maclennan, S.; Baraldi, P.G.; Borea, P.A. Hypoxiainhibits paclitaxel-induced apoptosis through adenosine-mediatedphosphorylation of bad in glioblastoma cells. Mol Pharmacol.2007, 72, 162-172.
66. Gan, P.P.; Pasquier, E.; Kavallaris, M. Class III β-tubulin mediatessensitivity to chemotherapeutic drugs in non small cell lung cancer.Cancer Res. 2007, 67, 9356-9363.
67. Raspaglio, G.; Filippetti, F.; Prislei, S.; Penci, R.; De Maria, I.; Cicchillitti, L.; Mozzetti, S.; Scambia, G.; Ferlini, C. Hypoxia inducesclass III β-tubulin gene expression by HIF-1alpha binding toits 3' flanking region. Gene. 2008, 409, 100-108.
68. Perez, E.A. Microtubule inhibitors: differentiating tubulininhibitingagents based on mechanisms of action, clinical activity,and resistance. Mol. Cancer Ther. 2009, 8, 2086-2095.
69. Cabral, F. Factors determining cellular mechanisms of resistance toantimitotic drugs. Drug Resist Updat. 2001, 4, 3-8.
70. Schiff, P.B.; Horwitz, S.B. Taxol stabilizes microtubules in mousefibroblast cells. Proc Natl Acad Sci USA. 1980, 77, 1561-1565.
71. Hunt JT. Discovery of ixabepilone. Mol Cancer Ther. 2009, 8,275-281.
72. Galmarini, C.M. Sagopilone, a microtubule stabilizer for thepotential treatment of cancer. Curr Opin Investig Drugs. 2009, 10,1359-1371.
73. Hoffmann, J.; Fichtner, I.; Lemm, M.; Lienau, P.; Hess-Stumpp, H.; Rotgeri, A.; Hofmann, B.; Klar, U. Sagopilone crosses theblood-brain barrier in vivo to inhibit brain tumor growth and metastases.Neuro Oncol. 2009, 11,158-166.
74. Downing, K.H. Structural basis for the interaction of tubulin withproteins and drugs that affect microtubule dynamics. Annu. Rev.Cell Dev. Biol. 2000, 16, 89-111.
75. Nettles, J.H.; Li, H.; Cornett, B.; Krahn, J.M.; Snyder, J.P.; Downing, K.H. The binding mode of epothilone A on α, β-tubulinby electron crystallography. Science. 2004, 305, 866-869.
76. Rieder, C.L.; Maiato, H. Stuck in division or passing through: whathappens when cells cannot satisfy the spindle assembly checkpoint.Dev Cell. 2004, 7, 637-651.
77. Gascoigne, K.E.; Taylor, S.S. How do anti-mitotic drugs kill cancercells? J. Cell Sci. 2009, 122, 2579-2585.
78. Brito, D.A.; Rieder, C.L. The ability to survive mitosis in the presenceof microtubule poisons differs significantly between humannontransformed (RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil.Cytoskeleton. 2009, 66, 437-447.
79. Gascoigne, K.E.; Taylor, S.S. Cancer cells display profound intraandinterline variation following prolonged exposure to antimitoticdrugs. Cancer Cell. 2008, 14, 111-122.
80. Brito, D.A.; Rieder, C.L. Mitotic checkpoint slippage in humansoccurs via cyclin B destruction in the presence of an active checkpoint.Curr. Biol. 2006, 16, 1194-1200.
81. Vakoc, B.J.; Lanning, R.M.; Tyrrell, J.A.; Padera, T.P.; Bartlett, L.A.; Stylianopoulos, T.; Munn, L.L.; Tearney, G.J.; Fukumura, D.; Jain, R.K.; Bouma, B.E. Three-dimensional microscopy of the tumormicroenvironment in vivo using optical frequency domain imaging.Nature Med. 2009, 15, 1219-1223.
82. Jordan, M.A.; Toso, R.J.; Thrower, D.; Wilson, L. Mechanism ofmitotic block and inhibition of cell proliferation by taxol at lowconcentrations. Proc Natl Acad Sci USA. 1993, 90, 9552-9556.
83. Horwitz, S.B.; Lothstein, L.; Manfredi, J.J.; Mellado, W.; Parness, J.; Roy, S.N.; Schiff, P.B.; Sorbara, L.; Zeheb, R. Taxol:mechanisms of action and resistance. Ann N Y Acad Sci. 1986, 466,733-744.
84. Giannakakou, P.; Sackett, D.L.; Kang, Y.K.; Zhan, Z.; Buters, J.T.; Fojo, T.; Poruchynsky, M.S. Paclitaxel-resistant human ovariancancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997, 272, 17118-17125.
85. Kavallaris, M.; Kuo, D.Y.; Burkhart, C.A.; Regl, D.L.; Norris, M.D.; Haber, M.; Horwitz, S.B. Taxol-resistant epithelial ovariantumors are associated with altered expression of specific betatubulinisotypes. J Clin Invest. 1997, 100, 1282-1293.
86. Berrieman, H.K.; Lind, M.J.; Cawkwell, L. Do β-tubulin mutationshave a role in resistance to chemotherapy? Lancet Oncol. 2004, 5,158-164.
87. Lu, Q.; Ludueña, R.F. Removal of βIII isotype enhances taxolinduced microtubule assembly. Cell Struct Funct. 1993, 18, 173-182.
88. Kavallaris, M.; Burkhart, C.A.; Horwitz, S.B. Antisense oligonucleotidesto class III β-tubulin sensitize drug-resistant cells toTaxol. Br J Cancer. 1999, 80, 1020-1025.
89. Kamath, K.; Wilson, L.; Cabral, F.; Jordan, M.A. βIII-Tubulininduces paclitaxel resistance in association with reduced effectson microtubule dynamic instability. J Biol Chem. 2005, 280,12902-12907.
90. Mozzetti, S.; Ferlini, C.; Concolino, P.; Filippetti, F.; Raspaglio, G.; Prislei, S.; Gallo, D.; Martinelli, E.; Ranelletti, F.O.; Ferrandina, G., Scambia, G. Class III β-tubulin overexpression is aprominent mechanism of paclitaxel resistance in ovarian cancer patients.Clin Cancer Res. 2005, 11, 298-305.
91. Freedman, H.; Huzil, J.T.; Luchko, T.; Ludueña, R.F.; Tuszynski, J.A. Identification and characterization of an intermediatetaxol binding site within microtubule nanopores and a mechanismfor tubulin isotype binding selectivity. J Chem Inf Model. 2009, 49,424-436.
92. Verdier-Pinard, P.; Shahabi, S.; Wang, F.; Burd, B.; Xiao, H.; Goldberg, G.L.; Orr, G.A.; Horwitz, S.B. Detection of human βVtubulinexpression in epithelial cancer cell lines by tubulin proteomics.Biochemistry. 2005, 44, 15858-15870.
93. Ferlini, C.; Raspaglio, G.; Mozzetti, S.; Cicchillitti, L.; Filippetti, F.; Gallo, D.; Fattorusso, C.; Campiani, G.; Scambia, G. The secotaxaneIDN5390 is able to target class III _-tubulin and to overcomepaclitaxel resistance. Cancer Res. 2005, 65, 2397-2405.
94. Magnani, M.; Ortuso, F.; Soro, S.; Alcaro, S.; Tramontano, A.; Botta, M. The βI/ βIII-tubulin isoforms and their complexes withantimitotic agents. Docking and molecular dynamics studies. FEBSJ. 2006, 273, 3301-3310.
95. Thomas, E.; Tabernero, J.; Fornier, M.; Conté, P.; Fumoleau, P.; Lluch, A.; Vahdat, L.T.; Bunnell, C.A.; Burris, H.A.; Viens, P.; Baselga, J.; Rivera, E.; Guarneri, V.; Poulart, V.; Klimovsky, J.; Lebwohl, D.; Martin, M. Phase II clinical trial of ixabepilone(BMS-247550), an epothilone B analog, in patients withtaxane-resistant metastatic breast cancer. J. Clin. Oncol. 2007, 25,3399-3406.
96. Thomas, E.S.; Gomez, H.L.; Li, R.K.; Chung, H.C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Pivot, X.B.; Klimovsky J.V.; de Mendoza, F.H.; Xu, B.; Campone, M.; Lerzo, G.L.; Peck, R.A.; Mukhopadhyay, P.; Vahdat, L.T.; Roché, H.H. Ixabepilone plus capecitabinefor metastatic breast cancer progressing after anthracyclineand taxane treatment. J. Clin. Oncol. 2007, 25, 5210-5217.
97. Ten Bokkel Huinink, W.W.; Sufliarsky, J.; Smit, W.M.; Spanik, S.; Wagnerova, M.; Hirte, H.W.; Kaye, S.; Johri, A.R.; Oza, A.M. Safety and efficacy of patupilone in patients with advancedovarian, primary fallopian, or primary peritoneal cancer: aPhase I, open-label, dose-escalation study. J. Clin. Oncol. 2009, 27,3097-3103.
98. Sabbatini, P.; Spriggs, D.R. Epothilones: better or more of thesame? J. Clin. Oncol. 2009, 27, 3079-3081.
99. Vansteenkiste, J.; Lara, P.N. Jr; Le Chevalier, T.; Breton, J.L.; Bonomi, P.; Sandler, A.B.; Socinski, M.A.; Delbaldo, C.; McHenry, B.; Lebwohl, D.; Peck, R.; Edelman, M.J. Phase II clinicaltrial of the epothilone B analog, ixabepilone, in patients withnon small-cell lung cancer whose tumors have failed firstline platinum-based chemotherapy. J. Clin. Oncol. 2007, 25, 3448-3455.
100. Mozzetti, S.; Iantomasi, R.; De Maria, I.; Prislei, S.; Mariani, M.; Camperchioli, A.; Bartollino, S.; Gallo, D.; Scambia, G.; Ferlini, C. Molecular mechanisms of patupilone resistance. Cancer Res. 2008,68, 10197-1204.
101. Lee, F.Y.; Borzilleri, R.; Fairchild, C.R.; Kamath, A.; Smykla, R.; Kramer, R.; Vite, G. Preclinical discovery of ixabepilone, a highlyactive antineoplastic agent. Cancer Chemother Pharmacol. 2008,63, 157-166.
102. O'Reilly, T.; Wartmann, M.; Brueggen, J.; Allegrini, P.R.; Floersheimer, A.; Maira, M.; McSheehy, P.M. Pharmacokinetic profileof the microtubule stabilizer patupilone in tumor-bearing rodentsand comparison of anti-cancer activity with other MTS in vitro andin vivo. Cancer Chemother Pharmacol. 2008, 62, 1045-1054.
103. Quick, Q.A. Epothilone B induces glioblastoma cell death viasurvivin down-regulation. Exp Oncol. 2008, 30, 195-201.
104. Failly, M.; Korur, S.; Egler, V.; Boulay, J.L.; Lino, M.M.; Imber, R.; Merlo, A. Combination of sublethal concentrations of epidermalgrowth factor receptor inhibitor and microtubule stabilizerinduces apoptosis of glioblastoma cells. Mol Cancer Ther. 2007, 6,773-781.
105. Silvani, A.; Gaviani, P.; Fiumani, A.; Scaioli, V.; Lamperti, E.; Eoli, M.; Botturi, A.; Salmaggi, A. Systemic sagopilone (ZKEPO)treatment of patients with recurrent malignant gliomas. JNeurooncol. 2009, 95, 61-64.
106. Gan, P.P.; McCarroll, J.A.; Po'uha, S.T.; Kamath, K.; Jordan, M.A.; Kavallaris, M. Microtubule dynamics, mitotic arrest, andapoptosis: drug-induced differential effects of βIII-tubulin. MolCancer Ther. 2010, 9, 1339-1348.
107. Risinger, A.L.; Jackson, E.M.; Polin, L.A.; Helms, G.L.; LeBoeuf, D.A.; Joe, P.A.; Hopper-Borge, E.; Ludueña, R.F.; Kruh, G.D.; Mooberry, S.L. The taccalonolides: microtubule stabilizers that circumventclinically relevant taxane resistance mechanisms. CancerRes. 2008, 68, 8881-8888.
108. Bai, R.; Edler, M.C.; Bonate, P.L.; Copeland, T.D.; Pettit, G.R.; Ludueña, R.F.; Hamel, E. Intracellular activation and deactivationof tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009, 75, 218-226.